Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. 1988

D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Medical Centre, Edgbaston Birmingham.

The survival benefit of second-look laparotomy after completion of primary chemotherapy in patients with epithelial ovarian cancer has been assessed in a prospective randomised trial of 166 patients. Patients were randomised into three groups. All were initially treated with cisplatin (100 mg/m2 x 5) after primary laparotomy. Group A (n = 53) was scheduled to have a second-look laparotomy, followed by cyclical oral chlorambucil. Group B (n = 56) was scheduled to have a second-look laparotomy, followed by total abdominal and pelvic irradiation, and group C (n = 57) received oral chlorambucil as for group A but had no second-look operation. With a median follow up of 46 months (range 21-64), no differences in survival were noted between the three groups. The median survival for group A was 21 months (95% CI 11-31 months), for group B 15 months (11-19), and for group C 17 months (8-26). Thus second-look laparotomy after completion of first-line single-agent cisplatin chemotherapy did not confer any survival benefit on patients with epithelial ovarian cancer.

UI MeSH Term Description Entries
D007813 Laparotomy Incision into the side of the abdomen between the ribs and pelvis. Minilaparotomy,Laparotomies,Minilaparotomies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012086 Reoperation A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery. Revision, Joint,Revision, Surgical,Surgery, Repeat,Surgical Revision,Repeat Surgery,Revision Surgery,Joint Revision,Revision Surgeries,Surgery, Revision
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
March 1994, Obstetrics and gynecology clinics of North America,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
January 2001, Current oncology reports,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
March 1989, European journal of cancer & clinical oncology,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
January 1990, Gynecologic oncology,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
December 1982, Gynecologic oncology,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
December 1994, Gynecologic oncology,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
January 1987, Harefuah,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
April 1986, Cancer,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
August 1993, Gynecologic oncology,
D Luesley, and F Lawton, and G Blackledge, and C Hilton, and K Kelly, and T Rollason, and T Wade-Evans, and J Jordan, and J Fielding, and T Latief
October 1996, Obstetrics and gynecology,
Copied contents to your clipboard!